) largely explained this P ! .001 observation.
Current guidelines recommend the use of tenofovir disoproxil fumarate (TDF) as one of the preferred nucleoside reversetranscriptase inhibitors (NRTI) for first-line antiretroviral therapy [1] . TDF was marketed in Spain in June 2002, although the drug had been widely available within an expanded access program since the middle of 2001.
Three main different patterns of drug resistance mutations may confer loss of susceptibility to TDF. K65R is the primary TDF resistance change in drug-naive subjects, and its selection clearly correlates with an impaired response to the drug [2] . In addition, K65R is known to reduce susceptibility to all other NRTIs except zidovudine [2] . Not surprisingly, the rate of K65R rapidly increased after TDF approval [3] . The other resistance mutations compromising TDF activity are T69S inserts and у3 thymidine-associated mutations (TAMs), including M41L and L210W [4, 5] . The emergence of the K70E mutation has also recently been linked to failure of TDF therapy [6] . The aim of this study was to assess retrospectively trends in the prevalence of these TDF-associated resistance patterns and determine which factors are associated with their selection in a relatively large population of patients treated with TDF.
Patients and methods. All HIV drug resistance tests performed during the period January 2000-December 2006 on samples from antiretroviral-experienced patients with plasma HIV RNA levels 11000 copies/mL in a reference laboratory located in Madrid, Spain, were retrospectively examined. A case report form was filled out for each sample, in which sex, age, risk category, viral load, CD4 + cell count, and current and past antiretroviral therapies were recorded in a computerized database. HIV pol sequences were generated from plasma specimens. Genetic sequence analyses were performed using ViroSeq (Abbott Molecular Diagnostics). For the purpose of this study, only mutations associated with reduced susceptibility to TDF, according to the latest International AIDS Society-USA panel list, were considered [7] .
To compare trends in the emergence of TDF-associated resistance patterns over time with changes in the prescription of antiretroviral therapy, the proportion of patients receiving antiretroviral therapy-and specifically, the number receiving TDF-was recorded using clinical charts and the hospital pharmacy registry. Of a total of 1177 samples examined, obtained from 767 different patients with HIV infection who were experiencing failure of antiretroviral therapy during the study period and for whom drug resistance testing results were available, 374 (31.7%) were from patients who experienced failure of treatment with TDF. If the study period was restricted to the time since TDF was marketed, 996 samples from patients who experienced failure of antiretroviral therapy were available for analysis; of these, 374 (37.5%) belonged to patients who ex- perienced failure of treatment with TDF. As expected, virus with TDF-associated resistance mutations was significantly more prevalent among patients who experienced failure of TDF therapy than among patients experiencing failure of treatment with other NRTI-containing regimens (table 1) . Of note, all but 1 K70E mutation occurred in isolates from patients with virus harboring either K65R or у3 TAMs.
The rate of distinct TDF-associated resistance patterns changed significantly over time. K65R was found in !1% of isolates before 2001; however, the rate of K65R rapidly increased to 14% of isolates in 2002, which was coincident with TDF marketing. It decreased to 2.7% of isolates in the period 2005-2006 ( ). In contrast, the rate of у3 TAMs steadily in-P ! .001 creased, from 33% of isolates in the period 2002-2004 to 44.1% of isolates in the period 2005-2006 ( ). The prevalence P p .02 of T69S inserts remained fairly stable at ∼1% over the entire study period ( figure 2) .
Overall, the decrease in the incidence of K65R was mainly associated with a reduction in the prescription of the combination of TDF plus didanosine, which accounted for 41.6% of all TDF-including regimens in 2003 but only 0.8% of such regimens in 2006 ( ). In the univariate analysis, selection P ! .001 of K65R in patients receiving TDF regimens was associated with coadministration of didanosine, compared with administration of another NRTI (20.3% vs. 5.9%;
) and compared with P ! .001 administration of abacavir (26.2% vs. 8.1%;
). No sta-P ! .001 tistically significant association was found between selection of K65R and administration of other NRTIs, such as lamivudine or stavudine. Conversely, a significant inverse correlation was observed for K65R in patients who were experiencing failure of TDF therapy and were receiving zidovudine concomitantly, because none of these patients had virus that developed K65R (0% vs. 11.8%;
). In the multivariate analysis, the P p .042 prescription of TDF, didanosine, abacavir, and M184V were independently associated with the presence of K65R, whereas the number of TAMs was inversely associated with the presence of K65R (table 2) .
Discussion. TDF is currently one the most widely used NRTIs for the treatment of HIV infection. Its efficacy, favorable toxicity profile, and convenient dosing have made this drug one of-if not the most-popular for first-line treatment, as has been recorded in several guidelines [1] . However, the emergence of drug resistance (and, specifically, selection of K65R) has been a matter of concern in patients who experience failure of TDF therapy, because K65R may result in broad cross-resistance (it currently confers resistance to all NRTIs except zidovudine) [7] . In this study, we assessed the prevalence of TDF-associated resistance mutations in a relatively large group of patients who experienced failure of antiretroviral therapy and trends since the marketing of TDF in Spain in 2002.
The overall prevalence of virus with TDF-associated resistance mutations in patients who experienced failure of TDFcontaining regimens was relatively low in this study (!15%), except for the pattern of у3 TAMs including M41L and/or L210W, which had an overall prevalence of 36.6%. Our study shows that selection of K65R is associated with exposure not only to TDF but also to didanosine and abacavir. In other studies, K65R was selected in up to 4% of persons experiencing treatment failure of first-line regimens based on stavudine, lamivudine, and efavirenz [8] . This observation is consistent with the fact that K65R may compromise the antiviral activity of all NRTIs other than TDF (except for zidovudine) [2] . We and others have previously reported that the rate of K65R rapidly increased after the introduction of TDF in clinical practice [3] . It is noteworthy that this follow-up study showed a decrease in the rate of K65R in isolates from patients who experienced failure of therapy with TDF, from 17% of isolates in 2004 to 3.6% of isolates in 2005 to 0% of isolates in 2006. This decrease occurred despite a relatively elevated and stable rate of prescription of TDF over the course of the study period. The main determinant of selection of K65R in our study was the coadministration of didanosine or abacavir. In fact, the high incidence of K65R in earlier years could be directly linked to widespread prescription of the combination of TDF plus didanosine at our institution, which peaked in 2003 at ∼35% of all patients receiving antiretroviral therapy. The coadministration of TDF plus didanosine was popular at that time because of its simplicity (1 pill each administered once per day), relatively good gastrointestinal tolerance, and expected avoidance of overlapping resistance. This attractiveness, however, soon disappeared when unexpected and seemingly parodoxical decreases in CD4 + cell count [9] , mitochondrial toxicities (including pancreatitis), loss of body weight, and increased risk of hyperglycemia and diabetes [10] began to be reported. Furthermore, an open-label study was prematurely interrupted when a high rate of virological failure was noticed in drugnaive patients receiving TDF plus didanosine [11] . All patients in that study harbored viruses with M184V at the time of viral rebound, and one-half of those patients had virus with the K65R mutation. Similar results were obtained using the combination of TDF plus abacavir plus lamivudine in drug-naive individuals [12] . Both cross-resistance driven by selection of K65R and intracellular interactions between TDF and either didanosine and abacavir explained all of these findings. Although this knowledge has altered the use of TDF, there is no doubt that the availability of the coformulation of TDF with emtricitabine in a single pill has made the continuous use of TDF very attractive. In our study, this change in the use of TDF within the past 2 years has been associated with a dramatic reduction in the incidence of K65R. It should be noted that the most prevalent pattern of TDF resistance in our study was the presence of у3 TAMs including M41L and/or L210W. This is mainly attributable to the fact that most patients who experienced failure of TDF therapy had previously been exposed to zidovudine and/or stavudine. An inverse correlation between the presence of TAMs and K65R has already been shown [2, 3] , and patients taking zidovudine in combination with TDF generally do not develop infection with virus that has the K65R mutation. In our study, most failures of TDF therapy in recent years occurred in subjects with virus that carried multiple TAMs; therefore, K65R is no longer a major concern. Other potential changes associated with TDF resistance, such as inserts at codon 69 or K70E, are very rare and are generally seen in patients with virus that harbors multiple TAMs or K65R, respectively. In summary, selection of virus with K65R in patients with HIV infection who experience failure of antiretroviral therapy has significantly decreased in recent years (at present, to !1% of patients receiving HAART), despite a relatively high and stable rate of prescription of TDF as part of antiretroviral regimens. A wiser use of TDF and, in particular, avoidance of coadministration with didanosine seem to explain this observation.
